<SEC-DOCUMENT>0000879169-23-000014.txt : 20230502
<SEC-HEADER>0000879169-23-000014.hdr.sgml : 20230502
<ACCEPTANCE-DATETIME>20230502070157
ACCESSION NUMBER:		0000879169-23-000014
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230502
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230502
DATE AS OF CHANGE:		20230502

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INCYTE CORP
		CENTRAL INDEX KEY:			0000879169
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				943136539
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12400
		FILM NUMBER:		23876582

	BUSINESS ADDRESS:	
		STREET 1:		1801 AUGUSTINE CUT-OFF
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19803
		BUSINESS PHONE:		3024986700

	MAIL ADDRESS:	
		STREET 1:		1801 AUGUSTINE CUT-OFF
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19803

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INCYTE CORP
		DATE OF NAME CHANGE:	20030318

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INCYTE GENOMICS INC
		DATE OF NAME CHANGE:	20000710

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INCYTE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19930902
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>incy-20230502.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:2be89172-4e67-47e4-98b5-00a4d7540d6b,g:e70a2bf4-026d-4e74-9b06-879b1228d9e7,d:cbb48aa394a24dac8a8121500eb1acda--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>incy-20230502</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV80L2ZyYWc6ODRhZjA4YTNjOTIzNDFiNDkwYjlkMDA1NmVjNzNiM2MvdGFibGU6OTBlY2NjODhkYjNmNGYxYzg4ZTdlYzM5MWM1ODMzZjQvdGFibGVyYW5nZTo5MGVjY2M4OGRiM2Y0ZjFjODhlN2VjMzkxYzU4MzNmNF8wLTEtMS0xLTQ5MTkw_a1a93215-1279-4933-be48-d08af41b7828">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV80L2ZyYWc6ODRhZjA4YTNjOTIzNDFiNDkwYjlkMDA1NmVjNzNiM2MvdGFibGU6OTBlY2NjODhkYjNmNGYxYzg4ZTdlYzM5MWM1ODMzZjQvdGFibGVyYW5nZTo5MGVjY2M4OGRiM2Y0ZjFjODhlN2VjMzkxYzU4MzNmNF8xLTEtMS0xLTQ5MTkw_0663db39-9fd6-48fb-bf16-2a49064cc992">0000879169</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="incy-20230502.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="if324902632234da2870be77c05ce923a_D20230502-20230502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-02</xbrli:startDate><xbrli:endDate>2023-05-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="icbb48aa394a24dac8a8121500eb1acda_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGV4dHJlZ2lvbjo3NmY3MTAzMTRkOTE0MDQ0YmVmYjE5YWFjYWMwYjlmYl8xMjQ0_5e1620cd-c25a-4d8b-9da6-a994216f5159">8-K</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGV4dHJlZ2lvbjo3NmY3MTAzMTRkOTE0MDQ0YmVmYjE5YWFjYWMwYjlmYl8xMDk5NTExNjI5MDYy_a60264d1-822d-44b3-984a-724255d42944">May&#160;2, 2023</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGV4dHJlZ2lvbjo3NmY3MTAzMTRkOTE0MDQ0YmVmYjE5YWFjYWMwYjlmYl8xMjQ1_3ce4383c-e6b1-474d-88b6-cf985395c6fa">INCYTE CORPORATION</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6YWM5MGRhYmNmY2QzNDZmYzgwZTQxMzJiNmI0NTM4NzkvdGFibGVyYW5nZTphYzkwZGFiY2ZjZDM0NmZjODBlNDEzMmI2YjQ1Mzg3OV8wLTAtMS0xLTQ5MTkw_ada534b1-1b27-4c33-8cf3-e425bff64c6b">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6YWM5MGRhYmNmY2QzNDZmYzgwZTQxMzJiNmI0NTM4NzkvdGFibGVyYW5nZTphYzkwZGFiY2ZjZDM0NmZjODBlNDEzMmI2YjQ1Mzg3OV8wLTEtMS0xLTQ5MTkw_41bec39b-bca3-4743-894f-6c38b84af534">001-12400</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6YWM5MGRhYmNmY2QzNDZmYzgwZTQxMzJiNmI0NTM4NzkvdGFibGVyYW5nZTphYzkwZGFiY2ZjZDM0NmZjODBlNDEzMmI2YjQ1Mzg3OV8wLTItMS0xLTQ5MTkw_3190f0a8-1730-47de-83d1-505d9638b578">94-3136539</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(State or Other Jurisdiction of<br/>Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6MmQ1OTY0ZjdiMjVhNDA2MWE5YjZiZDljMDI1ZmVhMGQvdGFibGVyYW5nZToyZDU5NjRmN2IyNWE0MDYxYTliNmJkOWMwMjVmZWEwZF8wLTAtMS0xLTQ5MTkwL3RleHRyZWdpb246NzEwMTM4NTVmNDczNGY3ZGFkZmJjNzM3MzA0NzU5NWFfNA_5116eda5-9608-4e42-becc-0e6782a17cba">1801 Augustine Cut-Off</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6MmQ1OTY0ZjdiMjVhNDA2MWE5YjZiZDljMDI1ZmVhMGQvdGFibGVyYW5nZToyZDU5NjRmN2IyNWE0MDYxYTliNmJkOWMwMjVmZWEwZF8wLTAtMS0xLTQ5MTkwL3RleHRyZWdpb246NzEwMTM4NTVmNDczNGY3ZGFkZmJjNzM3MzA0NzU5NWFfNw_2a84cfc1-c479-4a67-957d-78c9a56940d0">Wilmington</ix:nonNumeric>, <ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6MmQ1OTY0ZjdiMjVhNDA2MWE5YjZiZDljMDI1ZmVhMGQvdGFibGVyYW5nZToyZDU5NjRmN2IyNWE0MDYxYTliNmJkOWMwMjVmZWEwZF8wLTAtMS0xLTQ5MTkwL3RleHRyZWdpb246NzEwMTM4NTVmNDczNGY3ZGFkZmJjNzM3MzA0NzU5NWFfMTE_d473db1a-d081-43cd-98aa-3c7848c0bf3f">DE</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6MmQ1OTY0ZjdiMjVhNDA2MWE5YjZiZDljMDI1ZmVhMGQvdGFibGVyYW5nZToyZDU5NjRmN2IyNWE0MDYxYTliNmJkOWMwMjVmZWEwZF8wLTEtMS0xLTQ5MTkw_e567c695-cdbe-4545-b3d5-8eb33272c709">19803</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGV4dHJlZ2lvbjo3NmY3MTAzMTRkOTE0MDQ0YmVmYjE5YWFjYWMwYjlmYl8zMjA_2ac7ef74-6d7d-4d33-a2fc-0e2ab8749d08">302</ix:nonNumeric>) <ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGV4dHJlZ2lvbjo3NmY3MTAzMTRkOTE0MDQ0YmVmYjE5YWFjYWMwYjlmYl8zMjQ_65b86ead-6ffa-4888-95bb-c4e2045eea7b">498-6700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including area code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6MTcyOTIxYzJkODkxNDRiNTllMTUwN2JiNDRiZjMzNmEvdGFibGVyYW5nZToxNzI5MjFjMmQ4OTE0NGI1OWUxNTA3YmI0NGJmMzM2YV8wLTAtMS0xLTQ5MTkw_c69843b2-a082-498e-afe2-3bd19a3ea6aa">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6MTcyOTIxYzJkODkxNDRiNTllMTUwN2JiNDRiZjMzNmEvdGFibGVyYW5nZToxNzI5MjFjMmQ4OTE0NGI1OWUxNTA3YmI0NGJmMzM2YV8yLTAtMS0xLTQ5MTkw_3736fe36-4942-48c9-923f-edb67b933f85">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6MTcyOTIxYzJkODkxNDRiNTllMTUwN2JiNDRiZjMzNmEvdGFibGVyYW5nZToxNzI5MjFjMmQ4OTE0NGI1OWUxNTA3YmI0NGJmMzM2YV80LTAtMS0xLTQ5MTkw_3cfa64fe-26b3-469a-99cc-f83d0210e867">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6MTcyOTIxYzJkODkxNDRiNTllMTUwN2JiNDRiZjMzNmEvdGFibGVyYW5nZToxNzI5MjFjMmQ4OTE0NGI1OWUxNTA3YmI0NGJmMzM2YV82LTAtMS0xLTQ5MTkw_941b244c-2cb9-422c-b96c-4e95575d246f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:37.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.293%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name of exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6ZjczNjY2YzliNzQyNDE5OThkMjJjYzhhZTRiMDUzYjgvdGFibGVyYW5nZTpmNzM2NjZjOWI3NDI0MTk5OGQyMmNjOGFlNGIwNTNiOF8xLTAtMS0xLTQ5MTkw_85594d99-d1e7-413b-8eb5-2728679a760c">Common Stock, $.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6ZjczNjY2YzliNzQyNDE5OThkMjJjYzhhZTRiMDUzYjgvdGFibGVyYW5nZTpmNzM2NjZjOWI3NDI0MTk5OGQyMmNjOGFlNGIwNTNiOF8xLTEtMS0xLTQ5MTkw_c949b82a-1564-4905-b1a5-863c11488013">INCY</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6ZjczNjY2YzliNzQyNDE5OThkMjJjYzhhZTRiMDUzYjgvdGFibGVyYW5nZTpmNzM2NjZjOWI3NDI0MTk5OGQyMmNjOGFlNGIwNTNiOF8xLTItMS0xLTQ5MTkw_c8ac727d-f76d-4f73-9959-d0d08eb07e9e">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b&#8212;2 of the Securities Exchange Act of 1934 (&#167; 240.12b&#8212;2 of this chapter).</span></div><div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGV4dHJlZ2lvbjo3NmY3MTAzMTRkOTE0MDQ0YmVmYjE5YWFjYWMwYjlmYl8xMjQz_1f2b55e6-f772-44fe-b2e2-d10691256108">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="icbb48aa394a24dac8a8121500eb1acda_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV83L2ZyYWc6MTlhNzBiODhkY2RiNGViM2EyOTY1M2JjNmRkOTliOTQvdGV4dHJlZ2lvbjoxOWE3MGI4OGRjZGI0ZWIzYTI5NjUzYmM2ZGQ5OWI5NF8xMDk5NTExNjI4MDc1_a60264d1-822d-44b3-984a-724255d42944">May&#160;2, 2023</ix:nonNumeric>, Incyte Corporation issued a press release announcing financial results for its first fiscal quarter ended March&#160;31, 2023. The full text of the press release is furnished as Exhibit 99.1.</span></div><div id="icbb48aa394a24dac8a8121500eb1acda_10"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Exhibits.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.173%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="incy-q12023xexx991.htm">Press release issued by Incyte Corporation dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="incy-q12023xexx991.htm">May 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="incy-q12023xexx991.htm">, 2023.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="icbb48aa394a24dac8a8121500eb1acda_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.326%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: <ix:nonNumeric contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xMy9mcmFnOjkwNWI5NWJlYjg2MjQ1NDRhMzI3NTE4N2M4OTk0NGY3L3RhYmxlOjBiMGNjNzg0YWIwNTQzOGVhMDY2N2VhNzFiZTNjOTUwL3RhYmxlcmFuZ2U6MGIwY2M3ODRhYjA1NDM4ZWEwNjY3ZWE3MWJlM2M5NTBfMC0wLTEtMS01NTg2OQ_a60264d1-822d-44b3-984a-724255d42944">May 2, 2023</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INCYTE CORPORATION</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Christiana Stamoulis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christiana Stamoulis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President and<br/>Chief Financial Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>incy-q12023xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i33535006aa234a16a6edf85e1492f3e1_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:12pt"><img alt="incy-20220802xex99d1001.jpg" src="incy-20220802xex99d1001.jpg" style="height:53px;margin-bottom:5pt;vertical-align:text-bottom;width:180px"></div><div style="margin-top:12pt"><font><br></font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FOR IMMEDIATE RELEASE</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Incyte Reports 2023 First Quarter Financial Results and </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Provides Updates on Key Clinical Programs</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13pt">Total net product revenues of $693 million in Q1'23 (+14% Y&#47;Y)</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13pt">Jakafi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (ruxolitinib) net product revenues of $580 million (+7% Y&#47;Y) in Q1'23&#59; raising the bottom end of full year guidance to new range of $2.55 - $2.63 billion for FY 2023</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13pt">Opzelura</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> (ruxolitinib) cream approved as the first and only treatment for repigmentation of nonsegmental vitiligo in Europe&#59; continued strong U.S. launch in atopic dermatitis and vitiligo</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13pt">Multiple positive data readouts from dermatology portfolio at AAD and EHSF 2023</font></div><div style="margin-top:12pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13pt">Conference Call and Webcast Scheduled Today at 8&#58;00 a.m. ET</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WILMINGTON, Del. &#8211; May&#160;2, 2023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Incyte (Nasdaq&#58;INCY) today reports 2023 first quarter financial results, and provides a status update on the Company&#8217;s clinical development portfolio. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Our first quarter results demonstrate continued year-over-year double-digit revenue growth driven by Jakafi, which grew across all indications, and Opzelura, which is on track to become one of the most successful dermatology launches in recent years. In addition, we further expanded our commercial portfolio with several regulatory approvals including Opzelura for vitiligo in Europe.&#8221; said Herv&#233; Hoppenot, Chief Executive Officer, Incyte. &#34;Furthermore, in Q1 we made a decision to focus our development efforts on eight programs that have high potential value for us and discontinued six other programs. This allows us to optimize our allocation of resources on programs that can have a high impact for patients and for Incyte.&#34; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Product Sales Performance</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jakafi&#58; </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net product revenues of $580 million&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Net product revenues grew 7% compared with the first quarter of 2022, driven by strong underlying patient demand growth (+7% Y&#47;Y) including an 8% growth in new patients. Total patients grew across myelofibrosis (MF), polycythemia vera (PV) and graft-versus-host disease (GVHD). </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Net product revenues were unfavorably impacted by&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Higher gross-to-net deductions, compared to fourth quarter of 2022, as a result of the Medicare coverage gap and higher commercial patient deductibles at the beginning of the plan year, as well as an increase in 340B orders.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lower than normal levels of channel inventory at the end of Q1, representing an $11 million impact.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opzelura&#58; </font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net product revenues of $57 million&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Net product revenues grew 343% compared with the first quarter of 2022, driven by growth in patient demand and expansion in payer coverage as the launch in atopic dermatitis (AD) and vitiligo continues. </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Compared to the fourth quarter of 2022, net product revenues were unfavorably impacted by&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increase in co-pay assistance due to higher commercial patient deductibles at the beginning of the plan year, consistent with first quarter dynamics and higher Medicaid utilization volume.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acceleration of refills in December 2022 driven by patient demand in advance of annual deductible reset or health plan changes that negatively impacted refills during the months of January and February this year.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pipeline Updates</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MPNs and GVHD &#8211; key highlights</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIMBER (Leadership In MPNs and GVHD BEyond Ruxolitinib)&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our LIMBER development program encompasses multiple monotherapy and combination strategies, with the goal of improving upon the standard of care in MF, PV, GVHD and now, essential thrombocythemia (ET). </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Combination trials of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ruxolitinib BID with zilurgisertib (ALK2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> INCB57643 (BET)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are ongoing and progressing well. </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">In early development, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCA33989 (mCALR) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is on track for initiating first-in-human study in MF and ET in 2023. Additionally, a Phase 1 study evaluating ruxolitinib BID in combination with Cellenkos' </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CK0804</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in MF is continuing to recruit patients.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">AGAVE-201, a global pivotal Phase 2 trial of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">axatilimab</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with cGVHD is ongoing and results are on track for mid-2023. A Phase 1&#47;2 combination trial of axatilimab in combination with ruxolitinib is being planned.  </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The Phase 3 LIMBER-304 trial, evaluating </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">parsaclisib in combination with ruxolitinib BID</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in suboptimal responders in MF and the Phase 3 LIMBER-313 trial, evaluating </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">parsaclisib in combination with ruxolitinib BID</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in first-line MF, were discontinued following results of interim analyses that indicated that the studies were unlikely to meet their primary endpoints in the intent-to-treat patient population. The studies were not stopped due to safety.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The U.S. Food and Drug Administration (FDA) issued a complete response letter for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ruxolitinib extended-release (XR) tablets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for once-daily (QD) use in the treatment of certain types of MF, PV and GVHD. Incyte will work with the FDA to determine appropriate next steps.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indication and status</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ruxolitinib XR (QD)<br>(JAK1&#47;JAK2)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myelofibrosis, polycythemia vera and GVHD</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ruxolitinib + zilurgisertib<br>(JAK1&#47;JAK2 + ALK2)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myelofibrosis&#58; Phase 2</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ruxolitinib + INCB57643<br>(JAK1&#47;JAK2 + BET)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myelofibrosis&#58; Phase 2</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ruxolitinib + CK0804</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(JAK1&#47;JAK2 + CB-Tregs)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myelofibrosis&#58; Phase 1 (LIMBER-TREG108)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Axatilimab (anti-CSF-1R)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chronic GVHD&#58; Pivotal Phase 2 (third-line plus therapy) (AGAVE-201)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ruxolitinib + axatilimab</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(JAK1&#47;JAK2 + anti-CSF-1R)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chronic GVHD&#58; Phase 1&#47;2 in preparation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCA33989 <br>(mCALR)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myelofibrosis, essential thrombocythemia&#58; Entering clinic in 2023</font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Development collaboration with Cellenkos, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Clinical development of axatilimab in GVHD conducted in collaboration with Syndax Pharmaceuticals.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Hematology&#47;Oncology &#8211; key highlights</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Zynyz&#8482; (retifanlimab-dlwr) approved for Merkel cell carcinoma in the U.S.&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zynyz, a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), received accelerated approval for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) in the U.S. This represents the first regulatory approval for Incyte's PD-1 inhibitor, which is also being evaluated in pivotal trials in non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the anal canal (SCAC).</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Monjuvi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(tafasitamab-cxix)&#47;Minjuvi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (tafasitamab)&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minjuvi continues to launch in new ex-US markets, having gained reimbursement in two additional countries this quarter, bringing the total of launch markets to six. At the American Association for Cancer Research (AACR), final five-year follow-up data from the Phase 2 L-MIND study were presented, which showed that Monjuvi plus lenalidomide followed by Monjuvi monotherapy provided prolonged, durable responses in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pemazyre</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (pemigatinib) continues to expand in ex-U.S. markets in cholangiocarcinoma and myeloproliferative neoplasms (MLNs)&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pemazyre was approved in Japan by the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of MLNs with FGFR1 fusion. MLNs are a rare, aggressive group of cancers characterized by an over-production of myeloid cells, or bone tissue, with the tendency to rapidly progress to an acute myeloid leukemia (AML). The launch of Pemazyre in cholangiocarcinoma (CCA) is ongoing in 10 key markets in Europe. In clinical development, FIGHT-210, evaluating pemigatinib in NSCLC, was discontinued.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Parsaclisib in warm autoimmune hemolytic anemia (wAIHA)&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Based on the challenging regulatory landscape associated with the PI3K class, development of parsaclisib in wAIHA has been discontinued.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indication and status</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pemigatinib (Pemazyre</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(FGFR1&#47;2&#47;3)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myeloid&#47;lymphoid neoplasms (MLN)&#58; approved in the U.S. and Japan<br>Cholangiocarcinoma (CCA)&#58; Phase 3 (FIGHT-302) <br>Glioblastoma&#58; Phase 2 (FIGHT-209)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tafasitamab (Monjuvi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#47;Minjuvi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(CD19)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)&#58; Phase 3 (B-MIND)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First-line DLBCL&#58; Phase 3 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">frontMIND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Relapsed or refractory follicular lymphoma (FL) and relapsed or refractory marginal zone lymphoma (MZL)&#58; Phase 3 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inMIND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Retifanlimab (Zynyz&#8482;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(PD-1)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merkel cell carcinoma&#58; approved in the U.S. <br>Squamous cell anal cancer (SCAC)&#58; Phase 3 (POD1UM-303) <br>Non-small cell lung cancer (NSCLC)&#58; Phase 3 (POD1UM-304)<br>MSI-high endometrial cancer&#58; Phase 2 (POD1UM-101, POD1UM-204) </font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCB99280 <br>(Oral PD-L1)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Solid tumors&#58; Phase 1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KRAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">G12C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-mutated solid tumors&#58; Phase 1&#47;1b in combination with adagrasib</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in preparation</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCB99318<br>(Oral PD-L1)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Solid tumors&#58; Phase 1</font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Development of tafasitamab in collaboration with MorphoSys.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Retifanlimab licensed from MacroGenics.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Clinical trial collaboration and supply agreement with Mirati Therapeutics. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflammation and Autoimmunity (IAI) &#8211; key highlights</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Dermatology</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opzelura  </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Opzelura approved for vitiligo in Europe&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opzelura was approved by the European Commission for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents 12 years of age and older. The EC decision is based on data from two pivotal Phase 3 clinical trials (TRuE-V1 and -V2), which showed treatment with Opzelura resulted in significant improvements in facial and total body repigmentation versus vehicle at Week 24 and among completers of an open-label extension at Week 52. Opzelura was well-tolerated with no serious treatment-related adverse events related to ruxolitinib cream.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Opzelura 104-week safety and efficacy data in vitiligo provide insights into the value of long-term treatment&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104-week results from the long-term extension of the Phase 3 TRuE-V study were presented at the American Academy of Dermatology (AAD) Annual Meeting. The data demonstrated that many patients who achieved a high level of facial repigmentation (&#8805;F-VASI90) at Week 52 were able to maintain durable response one year following withdrawal of treatment.  In patients who did not achieve &#8805;F-VASI90 at Week 52 and continued treatment with Opzelura, improvements in facial and total body repigmentation, as shown by greater proportions of patients reaching F-VASI75 and T-VASI50, were observed through Week 104.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Ruxolitinib cream in pediatric atopic dermatitis (AD)&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 3 trial of ruxolitinib cream in pediatric AD has completed enrollment with results expected by end of year. There are an estimated 2-3 million pediatric AD patients (ages 2-11) in the United States. </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Ruxolitinib cream in other indications&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte continues to expand the development of ruxolitinib cream into new indications as we seek to maximize the potential opportunity with the franchise. Phase 2 trials evaluating ruxolitinib cream in mild to moderate hidradenitis suppurativa (HS), lichen planus (LP) and lichen sclerosus (LS) are ongoing. Additionally, two Phase 3 trials evaluating ruxolitinib cream in prurigo nodularis (PN) were initiated.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Povorcitinib </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Phase 2 results in hidradenitis suppurativa&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52-week results from the Phase 2 study evaluating povorcitinib (15mg QD, 45mg QD, 75mg QD) in HS were presented as an oral presentation at the European Hidradenitis Suppurativa Foundation (EHSF) Annual Meeting. The data demonstrated that continuation of treatment with povorcitinib 75 mg resulted in sustained and durable efficacy across all treatment arms, and importantly, 22-29% of patients treated for 52-weeks achieved HiSCR100, which is defined as a 100% reduction from baseline in total abscess and nodule (AN) count with no increase from baseline in abscess or draining tunnel count. Povorcitinib is currently in two Phase 3 studies in moderate to severe HS. </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Phase 2 results in vitiligo&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36-week results from the Phase 2b study evaluating povorcitinib in patients with extensive vitiligo were presented as an oral late-breaking presentation at the American Academy of Dermatology (AAD) Annual Meeting. The data demonstrated that treatment with oral povorcitinib was associated with substantial total body repigmentation in patients with extensive nonsegmental vitiligo, as measured by total Vitiligo Area Scoring Index (T-VASI) scores. Specifically, the study met its primary endpoint, and patients receiving povorcitinib experienced statistically superior improvements in T-VASI at Week 24 compared to placebo (povorcitinib 15 mg, &#8211;19.1%&#59; 45 mg, &#8211;17.8%&#59; 75 mg, &#8211;15.7% vs. placebo, +2.3%&#59; least squares mean &#91;LSM&#93; difference, P&#60;0.01). Incyte plans to move into Phase 3 development for povorcitinib in vitiligo, pending FDA regulatory discussions.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.46pt">Studies planned for asthma and chronic spontaneous urticaria&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte announced the expansion of povorcitinib development into other inflammatory and autoimmune diseases, including planning for two Phase 2 trials in asthma and chronic spontaneous urticaria.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indication and status</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ruxolitinib cream (Opzelura</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(JAK1&#47;JAK2)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AD&#58; Phase 3 pediatric study (TRuE-AD3)<br>Vitiligo&#58; Phase 3 (TRuE-V1, TRuE-V2)&#59; approved in the U.S. and Europe<br>Lichen planus&#58; Phase 2 <br>Lichen sclerosus&#58; Phase 2 <br>Hidradenitis suppurativa&#58; Phase 2<br>Prurigo nodularis&#58; Phase 3 initiated (TRuE-PN1, TRuE-PN2)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ruxolitinib cream + UVB<br>(JAK1&#47;JAK2 + phototherapy)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vitiligo&#58; Phase 2</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Povorcitinib <br>(JAK1)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hidradenitis suppurativa&#58; Phase 2b&#59; Phase 3 (STOP-HS1, STOP-HS2)<br>Vitiligo&#58; Phase 2&#59; Phase 3 planned <br>Prurigo nodularis&#58; Phase 2<br>Asthma&#58; PoC planned<br>Chronic spontaneous urticaria&#58; PoC planned</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Auremolimab<br>(anti-IL-15R&#946;)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vitiligo&#58; Phase 1 in preparation</font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Novartis&#8217; rights to ruxolitinib outside of the United States under our Collaboration and License Agreement with Novartis do not include topical administration.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discovery and other early development &#8211; key highlights</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCB123667 (CDK2) oral presentation at the American Association for Cancer Research (AACR) 2023&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INCB123667 is a selective and potent CDK2 kinase inhibitor, which has been shown to suppress tumor growth as monotherapy and in combination with standard of care, in Cyclin E amplified tumor models, in vivo. At AACR, Incyte presented data demonstrating INCB123667 exhibited significant single-agent activity in vivo in CCNE1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">high</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> breast cancer xenograft and patient-derived xenograft models. INCB123667 is currently being evaluated in a Phase 1 clinical trial in patients with advanced malignancies including CCNE1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">high</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> TNBC and HR+HER2- tumors post-CDK4&#47;6 inhibitors.   </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCA33890 (TGF&#946;R2xPD-1) in clinical development&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> INCA33890 is a TGF&#946;R2xPD1 bispecific antibody which has been engineered to avoid the known toxicity of broad TGF&#946; pathway blockade.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INCA33890 has higher affinity for PD1 than TGF&#946;R2, and blocks TGF&#946;-signaling specifically in cells co-expressing PD-1, thus potentially sparing tissues where TGFb-signaling is important for normal function. Preclinical in vivo data presented at AACR show that INCA33890 has a greater anti-tumor effect than either individual benchmark antibodies or a simple combination of these.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development of the adenosine program (including INCB106385 and INCA00186), INCAGN1876 (GITR) and INCB81776 (AXL&#47;MER) has been discontinued based on early efficacy data.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Modality</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Candidates</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Small molecules</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INCB123667 (CDK2)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Monoclonal antibodies</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INCAGN2385 (LAG-3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, INCAGN2390 (TIM-3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bi-specific antibodies </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INCA32459 (LAG-3xPD-1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, INCA33890 (TGF&#946;R2xPD-1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Discovery collaboration with Agenus.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Development in collaboration with Merus</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Partnered &#8211; key highlights</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indication and status</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ruxolitinib</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(JAK1&#47;JAK2)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acute and chronic GVHD&#58; approved in Europe&#59; J-NDA under review</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baricitinib</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(JAK1&#47;JAK2)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AD&#58; approved in Europe and Japan <br>Severe AA&#58; approved in the U.S., Europe and Japan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Capmatinib</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(MET)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NSCLC (with MET exon 14 skipping mutations)&#58; approved in the U.S., Europe and Japan</font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Ruxolitinib (Jakavi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">) licensed to Novartis ex-U.S. for use in hematology and oncology excluding topical administration.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Baricitinib (Olumiant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">) licensed to Lilly&#58; approved as Olumiant in multiple territories globally for certain patients with moderate-to-severe rheumatoid arthritis&#59; approved as Olumiant in EU and Japan for certain patients with atopic dermatitis.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Capmatinib (Tabrecta</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">) licensed to Novartis.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 First Quarter Financial Results</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial measures presented in this press release for the three months ended March&#160;31, 2023 and 2022 have been prepared by the Company in accordance with U.S. Generally Accepted Accounting Principles (&#8220;GAAP&#8221;), unless otherwise identified as a Non-GAAP financial measure. Management believes that Non-GAAP information is useful for investors, when considered in conjunction with Incyte&#8217;s GAAP disclosures. Management uses such information internally and externally for establishing budgets, operating goals and financial planning purposes. These metrics are also used to manage the Company&#8217;s business and monitor performance. The Company adjusts, where appropriate, for expenses in order to reflect the Company&#8217;s core operations. The Company believes these adjustments are useful to investors by providing an enhanced understanding of the financial performance of the Company&#8217;s core operations. The metrics have been adopted to align the Company with disclosures provided by industry peers.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used in c</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">onjunction with and to supplement Incyte&#8217;s operating results as reported under GAAP. Non-GAAP measures may be defined and calculated differently by other companies in our industry.</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As changes in exchange rates are an important factor in understanding period-to-period comparisons, Management believes the presentation of certain revenue results on a constant currency basis in addition to reported results helps improve investors&#8217; ability to understand its operating results and evaluate its performance in comparison to prior periods. Constant currency information compares results between periods as if exchange rates had remained constant period over period. The Company calculates constant currency by calculating current year results using prior year foreign currency exchange rates and generally refers to such amounts calculated on a constant currency basis as excluding the impact of foreign exchange or being on a constant currency basis. These results should be considered in addition to, not as a substitute for, results reported in accordance with GAAP. Results on a constant currency basis, as the Company presents them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with GAAP.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Financial Highlights</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Highlights</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, in thousands, except per share amounts)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.990%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total GAAP revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">808,673&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">733,235&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total GAAP operating income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,770&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,540&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Non-GAAP operating income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,729&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,147&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP net income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,703&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,992&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP net income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,577&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,867&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP basic EPS</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.10&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.17&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP basic EPS</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.38&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.56&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP diluted EPS</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.10&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.17&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP diluted EPS</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.37&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.55&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revenue Details</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Details</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, in thousands)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.263%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.357%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%<br>Change<br>(as reported)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(constant currency)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jakafi</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">579,969&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">544,464&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Iclusig</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,685&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,069&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pemazyre</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,475&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,032&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minjuvi</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,556&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,502&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Opzelura</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,552&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,754&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">343&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">343&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">693,237&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">605,821&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty revenues&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jakavi</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,692&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,867&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Olumiant</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,155&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,064&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tabrecta</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,177&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,483&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pemazyre</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">412&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total royalty revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,436&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,414&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product and royalty revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">808,673&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728,235&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone and contract revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total GAAP revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">808,673&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">733,235&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM &#61; not meaningful</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NA &#61; not available</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Percentage change in constant currency is calculated using 2022 foreign exchange rates to recalculate 2023 results.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product and Royalty Revenues</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Product and royalty revenues for the three months ended March&#160;31, 2023 increased 11% over the prior year comparative period as a result of net product revenues increasing 14% year-over-year, primarily driven by increases in Jakafi and Opzelura net product revenues. The increase in Jakafi net product revenues was primarily driven by growth in patient demand across all indications and was partially offset by higher gross-to-net deductions for Medicare and commercial co-pay assistance consistent with historical prior years' first quarters, as well as an increase in 340B volumes. The quarter was also impacted by lower weeks on hand channel inventory than normal due to timing of certain customer purchases. Opzelura net product revenues for the quarter were $57 million, representing a 343% increase year-over-year driven by increased patient demand and expanded coverage. The quarter was negatively impacted by an increase in co-pay assistance due to higher commercial patient deductibles at the beginning of the plan year and higher Medicaid utilization volume.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, volume was negatively impacted by an acceleration of refills in December 2022 driven by patient demand in advance of annual deductible reset or health plan changes. Jakavi and Olumiant royalties for the quarter were impacted by unfavorable changes in foreign currency exchange rates, while Olumiant royalties were also impacted by a decrease in net product sales of Olumiant for use as a treatment for COVID-19.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating Expenses</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expense Summary</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, in thousands)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.506%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.962%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%<br>Change</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP cost of product revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,822&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,614&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP cost of product revenues</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,669&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,619&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP research and development</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">406,641&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353,373&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP research and development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">2</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375,620&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">327,045&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP selling, general and administrative</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">315,606&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,584&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP selling, general and administrative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">3</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294,017&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192,682&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP loss on change in fair value of acquisition-related contingent consideration</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,196&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,382&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP loss on change in fair value of acquisition-related contingent consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">4</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP (profit) and loss sharing under collaboration agreements</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,362)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,742&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(129&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Non-GAAP cost of product revenues excludes the amortization of licensed intellectual property for Iclusig relating to the acquisition of the European business of ARIAD Pharmaceuticals, Inc. and the cost of stock-based compensation.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Non-GAAP research and development expenses exclude the cost of stock-based compensation.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Non-GAAP selling, general and administrative expenses exclude the cost of stock-based compensation.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Non-GAAP loss on change in fair value of acquisition-related contingent consideration is null.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of product revenues</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> GAAP and Non-GAAP cost of product revenues for three months ended March&#160;31, 2023 increased 33% and 38%, respectively, compared to the same period in 2022 primarily due to product related costs for our commercial products including Opzelura. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> GAAP and Non-GAAP research and development expense for three months ended March&#160;31, 2023 increased 15%, compared to the same period in 2022 primarily due to continued investment in our late stage development assets and timing of certain expenses. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, general and administrative expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> GAAP and Non-GAAP selling, general and administrative expenses for the three months ended March&#160;31, 2023 increased 51% and 53%, respectively, compared to the same period in 2022, primarily due to expenses related to promotional activities to support the launch of Opzelura for the treatments of atopic dermatitis and vitiligo and timing of certain expenses.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Financial Information</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> GAAP and Non-GAAP operating income for the three months ended March&#160;31, 2023 decreased 79% and 48%, respectively, compared to the same period in 2022, primarily due to expenses related to promotional activities to support the launch of Opzelura for the treatments of atopic dermatitis and vitiligo and timing of certain expenses.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, cash equivalents and marketable securities position</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of March&#160;31, 2023 and December&#160;31, 2022, cash, cash equivalents and marketable securities totaled $3.1 billion and $3.2 billion, respectively. The decrease from December&#160;31, 2022 is due a reduction of our accounts payable balance at March&#160;31, 2023.  </font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 Financial Guidance</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte is tightening its full year 2023 guidance for Jakafi net product revenues as a result of its strong first quarter performance. Guidance does not include revenue from any potential new product launches or the impact of any potential future strategic transactions. Incyte&#8217;s guidance is summarized below.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Previous</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jakafi net product revenues</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2.55 - $2.63 billion</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2.53 - $2.63 billion</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Hematology&#47;Oncology net product revenues</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$215 - $225 million</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP Cost of product revenues</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 &#8211; 8% of net product revenues</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP Cost of product revenues</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 &#8211; 7% of net product revenues</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP Research and development expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,610 - $1,650 million</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP Research and development expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,485 - $1,520 million</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP Selling, general and administrative expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,050 - $1,150 million</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP Selling, general and administrative expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$965 - $1,060 million</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unchanged</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pemazyre in the U.S., EU and Japan and Iclusig and Minjuvi in the EU.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjusted to exclude the amortization of licensed intellectual property for Iclusig relating to the acquisition of the European business of ARIAD Pharmaceuticals, Inc. and the estimated cost of stock-based compensation.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Adjusted to exclude the estimated cost of stock-based compensation.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call and Webcast Information</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte will hold a conference call and webcast this morning at 8&#58;00 a.m. ET. To access the conference call, please dial 877-407-3042 for domestic callers or 201-389-0864 for international callers. When prompted, provide the conference identification number, 13737924.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you are unable to participate, a replay of the conference call will be available for 90 days. The replay dial-in number for the United States is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference identification number, 13737924.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conference call will also be webcast live and can be accessed at </font><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investor.incyte.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Incyte</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit </font><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and follow </font><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#64;Incyte</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Jakafi&#174; (ruxolitinib)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jakafi&#174; (ruxolitinib) is a JAK1&#47;JAK2 inhibitor approved by the U.S. FDA for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea&#59; intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults&#59; steroid-refractory acute GVHD in adult and pediatric patients 12 years and older&#59; and chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jakafi is a registered trademark of Incyte.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Opzelura</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (ruxolitinib) Cream 1.5%</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opzelura, a novel cream formulation of Incyte&#8217;s selective JAK1&#47;JAK2 inhibitor ruxolitinib, approved by the U.S. Food &#38; Drug Administration for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older, is the first and only treatment for repigmentation approved for use in the United States. Opzelura is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Use of Opzelura in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants, such as azathioprine or cyclosporine, is not recommended.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, Opzelura (ruxolitinib) cream 15mg&#47;g is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte has worldwide rights for the development and commercialization of ruxolitinib cream, marketed in the United States as Opzelura. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opzelura and the Opzelura logo are registered trademarks of Incyte</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Monjuvi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#47;Minjuvi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (tafasitamab) </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tafasitamab is a humanized Fc-modified CD19 targeting immunotherapy. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP).</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, Monjuvi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, Minjuvi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(tafasitamab) received conditional marketing authorization in combination with lenalidomide, followed by Minjuvi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in several ongoing combination trials.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minjuvi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Monjuvi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are registered trademarks of MorphoSys AG. Tafasitamab is co-marketed by Incyte and MorphoSys under the brand name Monjuvi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S., and marketed by Incyte under the brand name Minjuvi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe and Canada.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XmAb</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a registered trademark of Xencor, Inc.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Pemazyre</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (pemigatinib)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pemazyre is a kinase inhibitor indicated in the United States for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test*. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pemazyre is also the first targeted treatment approved for use in the United States for treatment of adults with relapsed or refractory myeloid&#47;lymphoid neoplasms (MLNs) with FGFR1 rearrangement.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Japan, Pemazyre is approved for the treatment of patients with unresectable biliary tract cancer (BTC) with a fibroblast growth factor receptor 2 (FGFR2) fusion gene, worsening after cancer chemotherapy.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, Pemazyre is approved for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pemazyre is a potent, selective, oral inhibitor of FGFR isoforms 1, 2 and 3 which, in preclinical studies, has demonstrated selective pharmacologic activity against cancer cells with FGFR alterations.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pemazyre is marketed by Incyte in the United States, Europe and Japan.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pemazyre is a trademark of Incyte.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Pemazyre</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(pemigatinib) &#91;Package Insert&#93;. Wilmington, DE&#58; Incyte&#59; 2020.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Iclusig</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (ponatinib) tablets</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ponatinib (Iclusig</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) targets not only native BCR-ABL but also its isoforms that carry mutations that confer resistance to treatment, including the T315I mutation, which has been associated with resistance to other approved TKIs.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, Iclusig is approved for the treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib&#59; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate&#59; or who have the T315I mutation, or the treatment of adult patients with Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib&#59; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate&#59; or who have the T315I mutation.</font></div><div style="margin-top:12pt"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Click here</font><font style="color:#4c4b53;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to view the Iclusig EU Summary of Medicinal Product Characteristics. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte has an exclusive license from Takeda Pharmaceuticals International AG to commercialize ponatinib in the European Union and 29 other countries, including Switzerland, UK, Norway, Turkey, Israel and Russia. Iclusig is marketed in the U.S. by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Zynyz&#8482; (retifanlimab-dlwr)</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zynyz (retifanlimab-dlwr), is an intravenous PD-1 inhibitor indicated in the U.S. for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zynyz is marketed by Incyte in the U.S. In 2017, Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc. for global rights to retifanlimab.</font></div><div style="margin-bottom:12pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zynyz is a trademark of Incyte.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the historical information set forth herein, the matters set forth in this release contain predictions, estimates and other forward-looking statements, including any discussion of the following&#58; Incyte&#8217;s potential for continued performance and growth&#59; Incyte&#8217;s financial guidance for 2023, including its expectations regarding sales of Jakafi&#59; expectations with respect to demand for and uptake of Opzelura&#59; the potential for ruxolitinib cream to expand into other indications&#59; expectations regarding the potential and progress of programs in our pipeline and the delivery of same&#59; expectations regarding ongoing clinical trials and clinical trials to be initiated, including the LIMBER program, INCA33989 (mCALR) in MF and ET, a Phase 1 study evaluating ruxolitinib BID in combination with Cellenkos' CK0804 in MF, axatilimab in cGVHD (alone and in combination with ruxolitinib), Incyte&#8217;s oral PD-L1 program, a phase 3 trial of ruxolitinib cream in pediatric AD, phase 2 and 3 trials of povorcitinib in multiple indications and a phase 1 trial of auremolimab in vitiligo&#59; our and our collaborators&#8217; potential for receiving additional regulatory approvals within the next 1-2 years and the corresponding potential for launches of new products and&#47;or indications&#59; Incyte&#8217;s plan to work with the FDA to determine next steps for ruxolitinib extended-release (XR) tablets for once-daily (QD) use&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expectations regarding ongoing launches by us and our collaborators&#59; and our expectations regarding 2023 newsflow items.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements are based on Incyte&#8217;s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to&#58; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development&#59; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules&#59; the effects of the COVID 19 pandemic and measures to </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">address the pandemic on Incyte&#8217;s clinical trials, supply chain and other third-party providers, sales and marketing efforts and business, development and discovery operations&#59; determinations made by the FDA, EMA, and other regulatory agencies&#59; Incyte&#8217;s dependence on its relationships with and changes in the plans of its collaboration partners&#59; the efficacy or safety of Incyte&#8217;s products and the products of Incyte&#8217;s collaboration partners&#59; the acceptance of Incyte&#8217;s products and the products of Incyte&#8217;s collaboration partners in the marketplace&#59; market competition&#59; unexpected variations in the demand for Incyte&#8217;s products and the products of Incyte&#8217;s collaboration partners&#59; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for Incyte&#8217;s products and the products of Incyte&#8217;s collaboration partners&#59; sales, marketing, manufacturing and distribution requirements, including Incyte&#8217;s and its collaboration partners&#8217; ability to successfully commercialize and build commercial infrastructure for newly approved products and any additional products that become approved&#59; greater than expected expenses, including expenses relating to litigation or strategic activities&#59; variations in foreign currency exchange rates&#59; and other risks detailed in Incyte&#8217;s reports filed with the Securities and Exchange Commission, including its annual report for the year ended December 31, 2022. Incyte disclaims any intent or obligation to update these forward-looking statements.</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;#&#160;&#160;&#160;#</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contacts</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Media</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investors</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Catalina Loveman</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+1 302 498 6171</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christine Chiou</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+1 302 274 4773</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">cloveman&#64;incyte.com</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">cchiou&#64;incyte.com</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><div id="i33535006aa234a16a6edf85e1492f3e1_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCYTE CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, in thousands, except per share amounts)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">693,237&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">605,821&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product royalty revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,436&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,414&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone and contract revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">808,673&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">733,235&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product revenues (including definite-lived intangible amortization)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,822&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,614&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">406,641&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353,373&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">315,606&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,584&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on change in fair value of acquisition-related contingent consideration</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,196&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,382&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Profit) and loss sharing under collaboration agreements</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,362)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,742&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">783,903&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616,695&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,770&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,540&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income and other, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,873&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,260&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(680)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on long term investments</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,318)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46,585)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,856&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,535&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,153&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,543&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,703&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,992&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.10&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.17&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.10&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.17&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income per share&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,960&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221,326&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225,589&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,950&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><div id="i33535006aa234a16a6edf85e1492f3e1_10"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCYTE CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, in thousands)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br>2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br>2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable securities</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,112,712&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,238,965&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">623,788&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">644,879&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741,701&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">739,310&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,849&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,298&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157,564&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,959&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216,694&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194,144&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128,313&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133,676&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,658&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129,219&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,593&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,593&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax asset</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">494,751&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">457,941&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,797,623&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,840,984&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable, accrued expenses and other liabilities</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,084,207&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,216,603&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,848&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,262&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,462,568&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,370,119&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,797,623&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,840,984&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><div id="i33535006aa234a16a6edf85e1492f3e1_13"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCYTE CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECONCILIATION OF GAAP NET (LOSS) INCOME TO SELECTED NON-GAAP ADJUSTED INFORMATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, in thousands, except per share amounts)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">GAAP Net Income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,703&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,992&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash stock compensation from equity awards (R&#38;D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">2</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,021&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,328&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash stock compensation from equity awards (SG&#38;A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">2</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,589&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,902&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash stock compensation from equity awards (COGS)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">2</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">769&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">611&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">3</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value of equity investments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">4</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,318&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,585&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of acquired product rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">5</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,384&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,384&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on change in fair value of contingent consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">6</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,196&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,382&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect of Non-GAAP pre-tax adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">7</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,511)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,425)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-GAAP Net Income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,577&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,867&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP net income per share&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.38&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.56&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.37&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.55&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares used in computing Non-GAAP net income per share&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,960&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221,326&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225,589&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,950&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Included within the Milestone and contract revenues line item in the Condensed Consolidated Statements of Operations (in thousands) for the three months ended March&#160;31, 2023 and 2022 are milestones of $0 and $5,000, respectively, earned from our collaborative partners. Included within the Research and development expenses line item in the Condensed Consolidated Statements of Operations (in thousands) for the three months ended March&#160;31, 2023 and 2022 are upfront consideration and milestones of $2,700 and $20,000, respectively, related to our collaborative partners.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> As included within the Cost of product revenues (including definite-lived intangible amortization) line item&#59; the Research and development expenses line item&#59; and the Selling, general and administrative expenses line item in the Condensed Consolidated Statements of Operations.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> As included within the Interest expense line item in the Condensed Consolidated Statements of Operations.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> As included within the Unrealized loss  on long term investments line item in the Condensed Consolidated Statements of Operations.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> As included within the Cost of product revenues (including definite-lived intangible amortization) line item in the Condensed Consolidated Statements of Operations. Acquired product rights of licensed intellectual property for Iclusig is amortized utilizing a straight-line method over the estimated useful life of 12.5 years.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> As included within the Loss on change in fair value of acquisition-related contingent consideration line item in the Condensed Consolidated Statements of Operations.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> Income tax effects of Non-GAAP pre-tax adjustments are calculated using an estimated annual effective tax rate, taking into consideration any permanent items and valuation allowances against related deferred tax assets.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>incy-20230502.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:2be89172-4e67-47e4-98b5-00a4d7540d6b,g:e70a2bf4-026d-4e74-9b06-879b1228d9e7-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:incy="http://www.incyte.com/20230502" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.incyte.com/20230502">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="incy-20230502_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="incy-20230502_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.incyte.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>incy-20230502_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:2be89172-4e67-47e4-98b5-00a4d7540d6b,g:e70a2bf4-026d-4e74-9b06-879b1228d9e7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_126badc6-ea7e-44ad-9394-246a7e218b79_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1fdaa84e-731b-4916-9df6-db5db9a39a42_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8da7fc12-5346-4868-b8c9-c1829673bb2d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3b9d1305-885c-478c-91a1-34ec45305489_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_711940ec-d440-44b5-be46-01e4cda491d9_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_c3274157-cec8-4c67-876c-43a398ba3286_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_1d404254-cbbb-4871-986a-7103b7ee62bf_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_10a07df4-c35e-4f49-8ed6-537ddf1bb748_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0f93398d-7011-41d3-b567-18776d7188cf_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9b24001d-9749-4ab9-9099-b8095e173088_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_41cea91b-3b86-4380-b7d6-8e8bb3ad0037_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_d32eb6be-b778-44d3-b594-680b00fd4e9b_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_11d8099c-0b31-441d-b571-63abe3aec929_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_38c18432-d40c-4553-b834-be82bfb420d0_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1b3e92bc-057c-4c87-a84a-131f2a4b95ed_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2cc3bae7-f015-4aa3-b1a6-b95be86c21a1_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_17701202-e543-4fef-8994-9bef6c909062_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_aef2214f-3581-44a1-9ba8-2e6d305d8307_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_6c376d4d-fb7e-4b07-af73-9cda2337530f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d563d2f7-8e52-4949-ab71-3847e05dac0b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5491d848-fa68-4a2e-8cae-08532a0e5178_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_2b78a3dc-e988-49de-a33e-dfd71c706968_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>incy-20230502_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:2be89172-4e67-47e4-98b5-00a4d7540d6b,g:e70a2bf4-026d-4e74-9b06-879b1228d9e7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.incyte.com/role/Cover" xlink:type="simple" xlink:href="incy-20230502.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c65e1734-92d6-4337-aa5e-0ac2ffa61bcc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4af294f1-6ae2-4eda-9798-7dc695c8c4cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c65e1734-92d6-4337-aa5e-0ac2ffa61bcc" xlink:to="loc_dei_DocumentType_4af294f1-6ae2-4eda-9798-7dc695c8c4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_211e4747-5449-40f5-820c-339f66d8bd8a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c65e1734-92d6-4337-aa5e-0ac2ffa61bcc" xlink:to="loc_dei_DocumentPeriodEndDate_211e4747-5449-40f5-820c-339f66d8bd8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b1ee88a3-456f-4890-9de5-10c5bf14bba5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c65e1734-92d6-4337-aa5e-0ac2ffa61bcc" xlink:to="loc_dei_EntityRegistrantName_b1ee88a3-456f-4890-9de5-10c5bf14bba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c7fc564b-3a6c-4ead-b9e3-797874f663c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c65e1734-92d6-4337-aa5e-0ac2ffa61bcc" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c7fc564b-3a6c-4ead-b9e3-797874f663c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8bd9ce4e-4ef9-4152-8e8d-a957fafd3c2e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c65e1734-92d6-4337-aa5e-0ac2ffa61bcc" xlink:to="loc_dei_EntityFileNumber_8bd9ce4e-4ef9-4152-8e8d-a957fafd3c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_5bc54fee-98b6-4846-9a6a-ea26dd768596" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c65e1734-92d6-4337-aa5e-0ac2ffa61bcc" xlink:to="loc_dei_EntityTaxIdentificationNumber_5bc54fee-98b6-4846-9a6a-ea26dd768596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_41f0c39d-cdc3-4a78-8ce3-e96e32b5bed8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c65e1734-92d6-4337-aa5e-0ac2ffa61bcc" xlink:to="loc_dei_EntityAddressAddressLine1_41f0c39d-cdc3-4a78-8ce3-e96e32b5bed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_32105945-58ba-4fcb-a3bb-9d30229e18b9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c65e1734-92d6-4337-aa5e-0ac2ffa61bcc" xlink:to="loc_dei_EntityAddressCityOrTown_32105945-58ba-4fcb-a3bb-9d30229e18b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_3f3b732d-d3f3-401a-ae2c-2cd58b27f3ac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c65e1734-92d6-4337-aa5e-0ac2ffa61bcc" xlink:to="loc_dei_EntityAddressStateOrProvince_3f3b732d-d3f3-401a-ae2c-2cd58b27f3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_1aab9511-3eea-4786-9513-aea67bceef06" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c65e1734-92d6-4337-aa5e-0ac2ffa61bcc" xlink:to="loc_dei_EntityAddressPostalZipCode_1aab9511-3eea-4786-9513-aea67bceef06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b0196487-5918-4f95-916c-d9071322d3ef" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c65e1734-92d6-4337-aa5e-0ac2ffa61bcc" xlink:to="loc_dei_CityAreaCode_b0196487-5918-4f95-916c-d9071322d3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_45019a14-2e05-4b03-bc72-3adac76a8ceb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c65e1734-92d6-4337-aa5e-0ac2ffa61bcc" xlink:to="loc_dei_LocalPhoneNumber_45019a14-2e05-4b03-bc72-3adac76a8ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_9b832947-a417-4335-a274-0c38f23ffc5c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c65e1734-92d6-4337-aa5e-0ac2ffa61bcc" xlink:to="loc_dei_WrittenCommunications_9b832947-a417-4335-a274-0c38f23ffc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_c86ebfc1-1b16-4f93-896e-9ea10de09ae9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c65e1734-92d6-4337-aa5e-0ac2ffa61bcc" xlink:to="loc_dei_SolicitingMaterial_c86ebfc1-1b16-4f93-896e-9ea10de09ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_194331da-91f0-4177-a2d5-897ffd451c09" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c65e1734-92d6-4337-aa5e-0ac2ffa61bcc" xlink:to="loc_dei_PreCommencementTenderOffer_194331da-91f0-4177-a2d5-897ffd451c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_d4e4159a-ad64-426e-b884-8d50d4907573" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c65e1734-92d6-4337-aa5e-0ac2ffa61bcc" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_d4e4159a-ad64-426e-b884-8d50d4907573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_cb4c1011-1f00-41cc-85ed-75ee936620de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c65e1734-92d6-4337-aa5e-0ac2ffa61bcc" xlink:to="loc_dei_Security12bTitle_cb4c1011-1f00-41cc-85ed-75ee936620de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ebe2b7e9-d57b-4717-a740-b886ec7cc077" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c65e1734-92d6-4337-aa5e-0ac2ffa61bcc" xlink:to="loc_dei_TradingSymbol_ebe2b7e9-d57b-4717-a740-b886ec7cc077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_cc87ede3-7a8e-40f0-b228-7f929205b035" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c65e1734-92d6-4337-aa5e-0ac2ffa61bcc" xlink:to="loc_dei_SecurityExchangeName_cc87ede3-7a8e-40f0-b228-7f929205b035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b340d671-6408-4706-bec3-71897cf32bd1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c65e1734-92d6-4337-aa5e-0ac2ffa61bcc" xlink:to="loc_dei_EntityEmergingGrowthCompany_b340d671-6408-4706-bec3-71897cf32bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_10a04ed4-d871-43bb-a917-63cc68ca81e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c65e1734-92d6-4337-aa5e-0ac2ffa61bcc" xlink:to="loc_dei_AmendmentFlag_10a04ed4-d871-43bb-a917-63cc68ca81e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_14219680-f7f7-4c07-87d7-30c23e19c001" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c65e1734-92d6-4337-aa5e-0ac2ffa61bcc" xlink:to="loc_dei_EntityCentralIndexKey_14219680-f7f7-4c07-87d7-30c23e19c001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>incy-20220802xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 incy-20220802xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !+ 0T# 2(  A$! Q$!_\0
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M+);&YE6$N5!RI57=QD?P9KO;J_T/P'X?A-Y>66A:-91I DEW.L$,2 !57<Q
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MHKMIQL?2O@C7)O$_@O0-9N(#:W&HZ?;W<D#*5,;21JY4@\C!.,&OEA5&F?\
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MN"^.O_))_$/_ %RC_P#1J5TX7^/3]5^9S8G^!/T?Y'>T445S'2%%%% 'P?\
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M91GWK,N?AQHUXC1W$NKSQ-]Z*36[UD8>A4S8(]B,5PI4^K?W?\$[VY]$OO\
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@:E%*4N9VG+?O;E7W:)]3TVBBBO$/:"BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140346407058016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  02,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INCYTE CORPORATION<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3136539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1801 Augustine Cut-Off<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wilmington<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">498-6700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INCY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000879169<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>incy-20230502_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="incy-20230502.xsd" xlink:type="simple"/>
    <context id="if324902632234da2870be77c05ce923a_D20230502-20230502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <startDate>2023-05-02</startDate>
            <endDate>2023-05-02</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV80L2ZyYWc6ODRhZjA4YTNjOTIzNDFiNDkwYjlkMDA1NmVjNzNiM2MvdGFibGU6OTBlY2NjODhkYjNmNGYxYzg4ZTdlYzM5MWM1ODMzZjQvdGFibGVyYW5nZTo5MGVjY2M4OGRiM2Y0ZjFjODhlN2VjMzkxYzU4MzNmNF8wLTEtMS0xLTQ5MTkw_a1a93215-1279-4933-be48-d08af41b7828">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV80L2ZyYWc6ODRhZjA4YTNjOTIzNDFiNDkwYjlkMDA1NmVjNzNiM2MvdGFibGU6OTBlY2NjODhkYjNmNGYxYzg4ZTdlYzM5MWM1ODMzZjQvdGFibGVyYW5nZTo5MGVjY2M4OGRiM2Y0ZjFjODhlN2VjMzkxYzU4MzNmNF8xLTEtMS0xLTQ5MTkw_0663db39-9fd6-48fb-bf16-2a49064cc992">0000879169</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGV4dHJlZ2lvbjo3NmY3MTAzMTRkOTE0MDQ0YmVmYjE5YWFjYWMwYjlmYl8xMjQ0_5e1620cd-c25a-4d8b-9da6-a994216f5159">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGV4dHJlZ2lvbjo3NmY3MTAzMTRkOTE0MDQ0YmVmYjE5YWFjYWMwYjlmYl8xMDk5NTExNjI5MDYy_a60264d1-822d-44b3-984a-724255d42944">2023-05-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGV4dHJlZ2lvbjo3NmY3MTAzMTRkOTE0MDQ0YmVmYjE5YWFjYWMwYjlmYl8xMjQ1_3ce4383c-e6b1-474d-88b6-cf985395c6fa">INCYTE CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6YWM5MGRhYmNmY2QzNDZmYzgwZTQxMzJiNmI0NTM4NzkvdGFibGVyYW5nZTphYzkwZGFiY2ZjZDM0NmZjODBlNDEzMmI2YjQ1Mzg3OV8wLTAtMS0xLTQ5MTkw_ada534b1-1b27-4c33-8cf3-e425bff64c6b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6YWM5MGRhYmNmY2QzNDZmYzgwZTQxMzJiNmI0NTM4NzkvdGFibGVyYW5nZTphYzkwZGFiY2ZjZDM0NmZjODBlNDEzMmI2YjQ1Mzg3OV8wLTEtMS0xLTQ5MTkw_41bec39b-bca3-4743-894f-6c38b84af534">001-12400</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6YWM5MGRhYmNmY2QzNDZmYzgwZTQxMzJiNmI0NTM4NzkvdGFibGVyYW5nZTphYzkwZGFiY2ZjZDM0NmZjODBlNDEzMmI2YjQ1Mzg3OV8wLTItMS0xLTQ5MTkw_3190f0a8-1730-47de-83d1-505d9638b578">94-3136539</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6MmQ1OTY0ZjdiMjVhNDA2MWE5YjZiZDljMDI1ZmVhMGQvdGFibGVyYW5nZToyZDU5NjRmN2IyNWE0MDYxYTliNmJkOWMwMjVmZWEwZF8wLTAtMS0xLTQ5MTkwL3RleHRyZWdpb246NzEwMTM4NTVmNDczNGY3ZGFkZmJjNzM3MzA0NzU5NWFfNA_5116eda5-9608-4e42-becc-0e6782a17cba">1801 Augustine Cut-Off</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6MmQ1OTY0ZjdiMjVhNDA2MWE5YjZiZDljMDI1ZmVhMGQvdGFibGVyYW5nZToyZDU5NjRmN2IyNWE0MDYxYTliNmJkOWMwMjVmZWEwZF8wLTAtMS0xLTQ5MTkwL3RleHRyZWdpb246NzEwMTM4NTVmNDczNGY3ZGFkZmJjNzM3MzA0NzU5NWFfNw_2a84cfc1-c479-4a67-957d-78c9a56940d0">Wilmington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6MmQ1OTY0ZjdiMjVhNDA2MWE5YjZiZDljMDI1ZmVhMGQvdGFibGVyYW5nZToyZDU5NjRmN2IyNWE0MDYxYTliNmJkOWMwMjVmZWEwZF8wLTAtMS0xLTQ5MTkwL3RleHRyZWdpb246NzEwMTM4NTVmNDczNGY3ZGFkZmJjNzM3MzA0NzU5NWFfMTE_d473db1a-d081-43cd-98aa-3c7848c0bf3f">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6MmQ1OTY0ZjdiMjVhNDA2MWE5YjZiZDljMDI1ZmVhMGQvdGFibGVyYW5nZToyZDU5NjRmN2IyNWE0MDYxYTliNmJkOWMwMjVmZWEwZF8wLTEtMS0xLTQ5MTkw_e567c695-cdbe-4545-b3d5-8eb33272c709">19803</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGV4dHJlZ2lvbjo3NmY3MTAzMTRkOTE0MDQ0YmVmYjE5YWFjYWMwYjlmYl8zMjA_2ac7ef74-6d7d-4d33-a2fc-0e2ab8749d08">302</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGV4dHJlZ2lvbjo3NmY3MTAzMTRkOTE0MDQ0YmVmYjE5YWFjYWMwYjlmYl8zMjQ_65b86ead-6ffa-4888-95bb-c4e2045eea7b">498-6700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6MTcyOTIxYzJkODkxNDRiNTllMTUwN2JiNDRiZjMzNmEvdGFibGVyYW5nZToxNzI5MjFjMmQ4OTE0NGI1OWUxNTA3YmI0NGJmMzM2YV8wLTAtMS0xLTQ5MTkw_c69843b2-a082-498e-afe2-3bd19a3ea6aa">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6MTcyOTIxYzJkODkxNDRiNTllMTUwN2JiNDRiZjMzNmEvdGFibGVyYW5nZToxNzI5MjFjMmQ4OTE0NGI1OWUxNTA3YmI0NGJmMzM2YV8yLTAtMS0xLTQ5MTkw_3736fe36-4942-48c9-923f-edb67b933f85">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6MTcyOTIxYzJkODkxNDRiNTllMTUwN2JiNDRiZjMzNmEvdGFibGVyYW5nZToxNzI5MjFjMmQ4OTE0NGI1OWUxNTA3YmI0NGJmMzM2YV80LTAtMS0xLTQ5MTkw_3cfa64fe-26b3-469a-99cc-f83d0210e867">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6MTcyOTIxYzJkODkxNDRiNTllMTUwN2JiNDRiZjMzNmEvdGFibGVyYW5nZToxNzI5MjFjMmQ4OTE0NGI1OWUxNTA3YmI0NGJmMzM2YV82LTAtMS0xLTQ5MTkw_941b244c-2cb9-422c-b96c-4e95575d246f">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6ZjczNjY2YzliNzQyNDE5OThkMjJjYzhhZTRiMDUzYjgvdGFibGVyYW5nZTpmNzM2NjZjOWI3NDI0MTk5OGQyMmNjOGFlNGIwNTNiOF8xLTAtMS0xLTQ5MTkw_85594d99-d1e7-413b-8eb5-2728679a760c">Common Stock, $.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6ZjczNjY2YzliNzQyNDE5OThkMjJjYzhhZTRiMDUzYjgvdGFibGVyYW5nZTpmNzM2NjZjOWI3NDI0MTk5OGQyMmNjOGFlNGIwNTNiOF8xLTEtMS0xLTQ5MTkw_c949b82a-1564-4905-b1a5-863c11488013">INCY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGFibGU6ZjczNjY2YzliNzQyNDE5OThkMjJjYzhhZTRiMDUzYjgvdGFibGVyYW5nZTpmNzM2NjZjOWI3NDI0MTk5OGQyMmNjOGFlNGIwNTNiOF8xLTItMS0xLTQ5MTkw_c8ac727d-f76d-4f73-9959-d0d08eb07e9e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xL2ZyYWc6NzZmNzEwMzE0ZDkxNDA0NGJlZmIxOWFhY2FjMGI5ZmIvdGV4dHJlZ2lvbjo3NmY3MTAzMTRkOTE0MDQ0YmVmYjE5YWFjYWMwYjlmYl8xMjQz_1f2b55e6-f772-44fe-b2e2-d10691256108">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV83L2ZyYWc6MTlhNzBiODhkY2RiNGViM2EyOTY1M2JjNmRkOTliOTQvdGV4dHJlZ2lvbjoxOWE3MGI4OGRjZGI0ZWIzYTI5NjUzYmM2ZGQ5OWI5NF8xMDk5NTExNjI4MDc1_a60264d1-822d-44b3-984a-724255d42944">2023-05-02</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate
      contextRef="if324902632234da2870be77c05ce923a_D20230502-20230502"
      id="id3VybDovL2RvY3MudjEvZG9jOmNiYjQ4YWEzOTRhMjRkYWM4YTgxMjE1MDBlYjFhY2RhL3NlYzpjYmI0OGFhMzk0YTI0ZGFjOGE4MTIxNTAwZWIxYWNkYV8xMy9mcmFnOjkwNWI5NWJlYjg2MjQ1NDRhMzI3NTE4N2M4OTk0NGY3L3RhYmxlOjBiMGNjNzg0YWIwNTQzOGVhMDY2N2VhNzFiZTNjOTUwL3RhYmxlcmFuZ2U6MGIwY2M3ODRhYjA1NDM4ZWEwNjY3ZWE3MWJlM2M5NTBfMC0wLTEtMS01NTg2OQ_a60264d1-822d-44b3-984a-724255d42944">2023-05-02</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ /#BB5I>*NQS
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M4$L! A0#%     @ /#BB5@=!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  \.*)69'/SU^X    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M"  \.*)6F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( #PXHE;?["C71@0  'T0   8
M      " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M"  \.*)6GZ ;\+$"  #B#   #0              @ &)#   >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( #PXHE:7BKL<P    !,"   +              "
M 64/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( #PXHE:JQ"(6,P$  "("   /
M              "  4X0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  \
M.*)6)!Z;HJT   #X 0  &@              @ &N$0  >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  \.*)699!YDAD!  #/ P  $P
M            @ &3$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 )
+ #X"  #=$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="incy-20230502.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="incy-20230502.htm">incy-20230502.htm</File>
    <File>incy-20230502.xsd</File>
    <File>incy-20230502_lab.xml</File>
    <File>incy-20230502_pre.xml</File>
    <File>incy-q12023xexx991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "incy-20230502.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "incy-20230502.htm"
     ]
    },
    "labelLink": {
     "local": [
      "incy-20230502_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "incy-20230502_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "incy-20230502.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "incy",
   "nsuri": "http://www.incyte.com/20230502",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20230502.htm",
      "contextRef": "if324902632234da2870be77c05ce923a_D20230502-20230502",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.incyte.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20230502.htm",
      "contextRef": "if324902632234da2870be77c05ce923a_D20230502-20230502",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000879169-23-000014-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000879169-23-000014-xbrl.zip
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MSYB+/1IPAO)=^-&5+N9V+;XZ)>VKGF1.W&']JM\PAJW0\GO#,[G7K2]:G?;
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MWZ2TN?E7&-]6Z+Z/&5161'Z!<2PUW'PD]_.]/&/(Z:/BDBC(_P9QM(DU>+@
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MR-+#)G+%CMTY_#/(PN#P_P%02P,$%     @ /#BB5K,Y2'AF @  : <  !$
M  !I;F-Y+3(P,C,P-3 R+GAS9,U576^;,!1]SZ_P>)XQD#0$U*326E6:E&U2
MUZI]FPQ<$JM@,]LTZ;^O[8!2TF9=I#V,%\R]Y]SO:\XOMG6%GD J)OC<"_W
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M/EAB:!OF=J)H_4SWQ'&>S1.9%*8P^(,;+29\/H,*^S@(,9!""//23"!@-.*
M0!\)HG44B+AMJMAU/[;D\(C0VT!LGPLL[!U6?S].CJSW+G1TDG=SU$Z"MK@;
M3,+-H6R+=H]5SRFN4W/Y.;_(;M,9]+E/5&RTBD(-<(P9H%I%($1$J1@*03!U
MFN!Z;&-L@GTZ:5,B-3QZ)5;'J:TM0CM.;+G1-/"T5BN&W*>T=CGH/Z&UY?/7
M3&?M!M4XF64Q=17XQU1F^7665_/BYX7)&Z?935KD]Z>9TC,_9L@4ZPH0'T*
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M(;%_WY)81TX_^D?[5^DIPH=)[/L9I+\(BA4(9^DS(M%!DF4$,((EFPR!DT5
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M^AL#-3(2=5A'%Y=SD[&M5Y+5KL^#=];/4UH>&AHE1Q?MKR7]O=*%-AC-V$X
M9N4FDS$(R=,\O\PW" ^I-^9GJS3K3*-?DA&]M,'CSIU*%UVKUEJ1<'F:ZIZ>
M'_;83LO%M23,LE!6CH$Y*VN*L^Y-=TA-CF6-^6ZH[;YPPIQWZMQI*]33J6*8
MA0UGA1=FH#/EFH?Y-]P+' H?O[G59A%+RD<LJ:BX.=2*F\I,[O6NBD4J>2X6
MJ13%(ELQ?PFN;2,,Q%0AZ-??OYW.3P]*^N*V3M@_2E>G[2A1SQ,/EG@\K'FP
M!+C/W+.,O')U!N9];9BK=QUBW GO+N73R2!H.>U+]HEIMY=/!5/F[CQ 3=WA
MHR'/*4OK66'IR[/[;*GG_%8V$$!IGAX[DB[OV3T33V!0JU7F?[=&(\Q\H.E7
MV(CDF<GPJ[!W$2#:]#275,W#T3_X=[ZEB>=;A> 62^Q7 ^/Q9!!.X$YJ/<13
MB8J/,0\KI"1Y-A!)6RDJE' ,^8=XBI.$5JT(R1."=AJE2UG![.C:#H<6=X*"
MR-](Y!>6;8]GA#GW60Q?:@,8VH&%N7V!\#S,X,:SM;[M=BF=$9G"@,WRN93[
MN'T@2/-2U#[0&X@0&0<T([#6P+.H@&NJVG_FY6>_I0S,Y>^::S">;T;;SK3%
M%1EM8IJRHWO>]801;*=?RR'Q6:Q,LI,+NSB2BG5K[(OE^0'[9P@K%A[\1>4R
MH,MN9>?'S&QA,>"QHV,O67/4--%/Y463L6K);VC$C6RJ&D\U&GA"8#%;,/"Q
M%R+<<(F5?4!0]<J)KBI4VT=2"3YH;, ?A,SBE?6_D]E)'>QJZ%!^.#<,\!"P
M DG**[(GO@H'!"0*T3:X$2-<&GS ?JV4/NY9L .0NSX-"]&TRLG7=ON&/JHG
MQPH+'9MZOF*.]J.%=@GV]I/U<Y3=C:.S\99Y:)1A2P[OR\+6+G ,B&=?IH@G
M-UE.S_6B"6X +#!\>J%-4+(<N!HK>;!(4."!F8-%MIZ(:OZ<_T99ZG*OLE8O
MJM/U&3T<$YYMEQ SM19X"_8CP$:ZZ=<#VCSJSR[GWSPE?^)R8"W@35@^30;I
MAF9?!+ R\$"B.L"^BZWH\,8)')+&=:/0 _F"J[C'5'5&$\(-7\YGL'T75R3[
MT-,BTWA-=M0-,5,\:M\+A(,ZDL'K:0. <MED-*8&;OXW] ,).WP)*KZ1A]UC
M%+F=IQ%*#6J>1UXEU32+GBW3\N=?C^T]X^UBC\BIMZ60B]N3+Y>=.'&+$58#
M=X)4I%XY1PCA@U4 SD"6SE$8EBHX\9<H4SX%T\F.XQ]76FH,\@DC<=,=15.G
M2*Q/<1/15(I^XJ%'Q':68\+^/-B!@*5F1]@NJV%?S&M869X($QG\YM0CU1.#
MJ$NL+ZA6@4_DA8>IN/+X:^"&-CHE5#0I*1@9<Y$R7!J:?"\8S$H+.2Y(#L>4
M,F%&?DP8.VY$S%&(8[%, BT$:GDBRA(=,.0$D:1#-YY%<-L(Y9"SN,DK%9N.
MH^IW:DWK1!VQL5= 3&*O):Z=0[P-? @<W9=; H^5_F >]42(YM*DBH^X$9#,
MGV%_ZNUKHFTO/T4]?"T?^%I9HE[$=&D]UH!'UKR'\^9"D: 4#W))K] :9 VP
M,<;2&$MV%8UF=DC9&.$^OGD@[)$?=QV>"+:X4P3O6EC-@+=.MD0=D!>0%JJ;
MJ.)8-DE."3E9X!YMFEH74[MC"0\0;IVY]:?Y/.IY["?OZHK@D<P(>3^2M=6;
MQ<^ XSZ'LMU] J (!9@B%'V>U@()D?N+@#KY';<>%5S+R6+QVD)?=MW&_44C
MQSR!DCEYRBP= >#ZB7T#Z@LG&!)?@V[G0Q1:?IKWGD4X]].!%=@7X!;(DJ:K
M1>M(7@\+E(7BSSTQUO;Q]B*)V14SMDR*S!0Y+8VZ*&"+;RO T\P>=DJ(GY(0
MX@*#3TJDVQ7(FUI]IQ5>Q#/TY5 A&89+H<4B"<6#XGP+A 65C,'B;"QUC\4>
M:8 %$HTZ_'J"'I=<C*V"4T0^938OW-6!UW+7LUO+G=E9R1.7\MO:V6CIXQ.<
M&"N\';G*:VTB*XL^"AT.<A3X69%^L!O"XTR0.B!!P0=%W@=Q2&: E-+':]@Y
MN4D3;#3*K=;RGV<2^A:<!,9[<%RDYXQ<N?+V6^5*[;6)D.^=)(EK72VA<W,Y
MDIO#66N59$HI$>9BF43KFY83L\'+Q4?K]Q0$NY1!L#,,@J'6H3@8TU5EG82-
MG8!]NU>^*ADO>TC&..8J-5(O[G:5S(F] =E..NUN9\^ME;)"[FG4$ 52(C=]
ME=+<3/+R9K)L*RP'6/O++(XVM/>366<K2YMN5II*O:'+HYKM  !_6A,0FTQ*
M*RAXORFXH>N*IM>R2,&1JIN)[J@UZ?EM+7DZDXID5XGB&W_&8=DODP"_Y1CN
M4.35CDFNU-;#U$*YGSD9J%651J/R.A&8(56]WTA2U;I2J^X02^]4^[5[R94<
M8Q^4]%J K7PP1K.E-+36FGRQF#:W*KU6M2SV$DEJ0U/4:F-W6%IB3%?7,J;7
M+V#*MCQXYRE-&W_& :@D4D2." H5E&'IIJE*H[)N%*Q00>^+)+VAM%K:SC70
M/GO^B>5\( (KM\YDLZK4&NM:8X7'_\XVLZ8IS?H.L50$H#,6/"X"T*O;S)C;
M:["SF[N\:J W"[2LH67M\\7\G")6RFK^X^<%P>6*X'9O&.QSW"5Q9?97CZSJ
MR6<--:NS]:(=9IRM]6;NPT@%P>6)X&KU(B2V;5_$M+"<SMQ++5(8AQEDZL(;
M*0BN\$;VT!O99TU2F(<99&Q]ASD[A3]R@ 176[<68]/^R"J]DC/9Y.$VZNES
M*@)NV?GK[[#J^K.RWF6M'?:R@4.M5M;J*\]YRHLMDI<K5T93JZS7JKEI-%&L
M=5MK;:STU,4)'MIS2=%[F,=1-!]9H_G(#& \]W$V VL5"GGFMEQ [ <$4(<:
MX.&GHU1'S.,5_/+-@^A9%^4];:=5X;<SXVZU!4:XS?@JC^9:&FYGJO%\X_AU
MIANM.L=E?H+ZC&**;>9#44S[T\.G:'NT-LBTU^J1 SA4O1+8K]LU0R-(6B31
M3)6\QL1S?.4;FJ/LNJ:P6.&[KW!#9W4R2J]G6TKA6+B>58BDXCBQ.-V16ZLU
M6DJKGO]>#07-Y8CFJE6E6J_FGN:29^QE<?:VL@RRQF@_K.((%Z11D,:&O/A<
M&,KGAAWZ5K^PE-_IRKVLEM<:2KWYRCZN&4I[WG,DU97*VO9_@:3W1=*Z!4&K
MXB=K:N=UMMA!DX:Z;O^D_:"-0XI:WH@A_W/LY;]Q4UZNW$NG3=.4:F.'F=R%
M9[V*-&\J%7V''?$*)*W"2=OBHJPIGB(TMCYM;.LH)=NT<4BQL4O+^6_X4)PB
M9\$:RZW;5E=J:[?Y**(N[XNCJE*K;,N[+G"T(1P5H;&"-I;E&:@'21N'%!J[
M'OTI[-#CA3&6 6,LMTY;#:VQ(NJ2;22IFM*H%4ECV4:27MW6S)6L:9XB-E80
MQ_L&Q[*\83FFT5E0!%989AFPS-X^&3USPJ3>PBGAK^QQF(LY]P>+V4I-:6JO
M]-WW#K/YPY^ZKI&^'V&7@C96H8UMI0-GFS8.H!_NK3OF=C NBO\S5_P?T=*6
M"M=7]6CW8H69?L8AY6!@(7^1@I$EWS)_MDBCKM37GCY<G.^_,Y(JNQVX6B!I
M!22M.R!K/XSZ@C16<?@.,S_GH'(P['!H<2<HK+$,6&,Y/AQ4U%T.FBA.<%?)
MMFPJE:)Q3\:1='0X-2BK=/8NJ&.:.M:VR/:$.@XI/';/NYXP@B(M-@LF66Y]
M-[#(&D7H)=LXTI5J<]VLN@)'[XLC;5NC?[.F=K8;'WM;QF3FJ.*J?; 1HZ*A
M38;,D]QZ,M6U6U\5D8CWQ="/'YN:JIWL#Y;>EK*5.?Q<76XU?K+?T#J8J@YO
M)K.OT-H9T-I[F/>OJC6EJK_RO'CO\O[W"K/8>_"U90%[A]G\X>_H8)(X7G>@
MM(4(QC9&=&49\O,%I-PQ"],CBZ;'RMGZ^1%PS4I3J3=>69V>#06UP4##/F&V
MH34537]E7M'>839_^%/7K0/.;;9"5D(Q!UM3=&G9P@] (9+I8<#U'B\:663+
M]MA#Y_AU0?)]=8[W";,U!1Y?X#6O00_UM<C+G^VQW;!'01Y[11X'$XWZVF[?
M%.9?1H;&1QI14L4G<"68Z89=6TBM^ :S(6NTM_;@[XU )M.R=A/AN3>!9\<A
MGH(W"MY8&N#4]3<'.//,&WL>_ES7QBS"GQL/?_X4<& )^->T'G[Y&?X3/VO(
MO;[E$'_4Z9Z-PJWY$MPTF93&?OQ85T^8XP9L*+@#>^B%=@+->,V[65P[M3C^
MP"T;(?G"VI9BZ,V+KI6U%99],G)]*[!<D ;"YH'U($X0PR6MC)N>91GN"WP
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M]PAV"D*)F6*([^:&Y_JP7=N&'TT0KLCE/BV+GL5!XL*/8X!#SX<WPK,&@"L
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MSD'4FF6UNMH@Q+4?JZ_TV!?R*M;(Y]ARIL5:YO;BP6,=FFV\2M_<[._E!D2
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MNBC@ ;P"+J[P)XN2U?)^;&9UKG\'[:>V&)H2E/Q#)0@@K4#J$W(//0E(+9*
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M5PCKC KKW!INC7HQI2+;&*JK^6\0M0]BVL+C5^$'>13!^@&(X/R:8I6BL*?
M4&$I+P5_9\"=/CS- L.86QY[X'8HF-N++>0%4P+R))QGD[&S)7(/W#ZN*;I:
M=%K/-HZJ=:767'<X=&$D;Q #[:$+2_U3!B] ,'-L\X!=F$>>:X9&(*="YE(Z
MUPY .N?6, /I_-IVF(7Q?!@X*LSG"]?W&<AE@\SH>2OZI?X[>9+6]0.0UKFU
MT^J*VEIW6%9A2[\WCO3F*]-N"U-Z$PBXYT\,H"G : ;9C-%G*CD9>5@;^L3X
M.^;@;D$^-PY /N?64CMJ*#55/2XLZ:SB1VTH5:VV$P0=0&E?(FN+\KZB.BK;
MU5'-JE)KO+*!>E'>5Q#PSC>M:IK2K&>2@C<RR6;]^J1,ZI%U]KJMB3L;+/7:
M^L2=3';37#W/B:P?!ZR?:'AFTOYHNC0QJZ3Y%B+>X%RGK3UC/Z8UKD:.G[EO
M&7FEN#>[GEG#QMKS]O)CB53*>O[3[PJ"RQ/!U=8]!,E>'"<7.N34PA:LYMYI
MD6*\6 :96B_FV14$]ZY:9/<9CT6,9 =!C*SWO,F%:7"'40V?A;XP,2$*BV]#
M3()B11BD"(-DB$YS'0;9[]-X3=.45GW=47#9BQWL.Y941=<*A[MPN \]^U;3
M:J_HRY,]+W7?L01:I;;K :-+YR.EIIS4-Y\A6RMK+P%)6YY[JI6;[]_L=;93
M_N*!2YA.9H<F.!N/5C"@43."75JV\ ,0032V$*LP/(ZE<N)!."&\&A_#K$ ,
M671#QW5,X:#+ I\HZX'F)]\%\ ]E!&/&\/4H*M_PV5%ZILTQZ[D>/2:@<19#
ME\99"!QGP6B6A:0Y7548SD*@16&'?X;C;X;Q6ND=?ZG0KW^IX2Q<!5;LCX2!
MB+#'"A/<<^"1U,+(#3WD5YMW78\PQ4;<"QSA^>6%(+D5OJ"Q&OAX$P!ANR/<
M&1-/V!PI8T )1[#)V:H9NF0&7)K2J$0@TRJ+8!:/P@[<YT V-WLH3^RG[9+]
MVM@\8)[<.JY/6?9)E6K,>D?R:@P(F*)G.4!P)1MVBL&"@#M]"_-&>*KH]7A"
MF#]^K+5.UJ5F>1->AS?>"1M^Z2NL+P#QW*8?N#F$A?A!1!4;XXA\DY6>0;(Z
MCSH%Q3@Z<!15,XBBWQQ/P#K_A&]M+(_$^DC;!78'S W3#44.''>U#.)N*U+[
MM=AE[<6M#O RVS+DH[!UF&V#N@]!EL-U<'LP)M/C'!;L6WUF^?'"X/(PL( T
M<1N<H;S'!Y9HI4,!IHO)7, 7K1:HU!K2 D-?]$(<AMVCFEY5*]?8&+1/SNFO
MGD'Z>ZF>FII?R,V68L-N68WU7H@757LM>AN[02\L6/ID>+H3) 67_DL5EV3U
MPSZ,T(Z8CIC42?$A=QQD<OE M-/P$8 KH<"G[W@Y" -WSF48XR$3[ @)!*E!
MCK)'DHJNL&WWD3L&SKCO<\OQ@\1G %$G/!1 M%C?%\$"HI@YJ=WW^<:S35O2
M_^VZYAC^&01#^Y?_#U!+ 0(4 Q0    ( #PXHE8Y3I:<H!0  .R%   1
M          "  0    !I;F-Y+3(P,C,P-3 R+FAT;5!+ 0(4 Q0    ( #PX
MHE:S.4AX9@(  &@'   1              "  <\4  !I;F-Y+3(P,C,P-3 R
M+GAS9%!+ 0(4 Q0    ( #PXHE8)I+)11@H  !A=   5              "
M 607  !I;F-Y+3(P,C,P-3 R7VQA8BYX;6Q02P$"% ,4    "  \.*)6LQH)
M>:<&  #8,   %0              @ '=(0  :6YC>2TR,#(S,#4P,E]P<F4N
M>&UL4$L! A0#%     @ /#BB5B*N<$2L6P  )6@$ !8              ( !
MMR@  &EN8WDM<3$R,#(S>&5X>#DY,2YH=&U02P4&      4 !0!( 0  EX0
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
